LAUSR

Background: Propofol is increasingly being used for sedation in gastrointestinal endoscopy; however, owing to its side effects, an alternative drug is needed. We aimed to compare the safety, satisfaction, and efficacy outcomes of etomidate versus propofol in patients undergoing gastrointestinal endoscopy, including advanced endoscopic procedures. Methods: We systematically searched Embase, PubMed, Cochrane Central Register of Controlled Trials, CINAHL (via EBSCO), China National Knowledge Infrastructure, and Web of Science (1946–April 2020) databases for randomized controlled trials of gastrointestinal endoscopy (upper gastrointestinal endoscopy, colonoscopy, and advanced endoscopy) using etomidate or propofol as sedatives. We pooled odds ratios (ORs) for the safety profile and patient and anesthesiologist satisfaction using mixed-effects conditional logistic models and standardized mean differences for efficiency outcomes using random-effects models. Results: Twenty-four studies involving 3875 patients were included. Compared with propofol, etomidate resulted in significantly reduced apnea (OR: 0.22; 95% confidence interval [CI]: 0.13–0.37; P < .001), hypoxemia (OR: 0.43; 95% CI: 0.35–0.54; P < .001), hypotension (OR: 0.20; 95% CI: 0.11–0.36; P < .001), and bradycardia (OR: 0.52; 95% CI: 0.30–0.91; P = .02) but led to increased myoclonus (OR: 8.54; 95% CI: 5.20–14.01; P < .001) and lowered anesthesiologist satisfaction (OR: 0.60; 95% CI: 0.39–0.91; P = .02). Conclusion: Etomidate may be a good alternative to propofol for gastrointestinal endoscopy, especially advanced endoscopy. Etomidate appears to be safe as an inducer for hemodynamically unstable patients or older adult patients undergoing gastrointestinal endoscopy.